– acute bacterial sinusitis (adequately diagnosed)

– acute bacterial otitis media (adequately diagnosed)

– pharyngitis, tonsillitis

– acute exacerbation of chronic bronchitis (adequately diagnosed)

– mild to moderately severe community acquired pneumonia

– skin and soft tissue infections

– uncomplicated Chlamydia trachomatis urethritis and cervicitis

Considerations should be given to official guidance on the appropriate use of antibacterial agents.

LUFTHER Dry Syrup offers several key advantages in the realm of malaria treatment:

Rapid Parasitic Clearance: Artemether’s rapid action ensures the swift reduction of parasite numbers, relieving symptoms and preventing complications.

Comprehensive Eradication: Lumefantrine’s sustained activity eliminates residual parasites, reducing the risk of disease recurrence and transmission.

Global Impact: The accessibility and effectiveness of LUFTHER Dry Syrup contribute to the global effort to control and eventually eliminate malaria.

Improved Patient Adherence: The formulation of LUFTHER Dry Syrup may enhance patient compliance, particularly in pediatric cases where swallowing tablets can be challenging.

CALTIS Dry Syrup offers several key advantages in the realm of infectious disease treatment:

Broad-Spectrum Coverage: Calithromycin’s spectrum of activity makes CALTIS Dry Syrup a versatile option for treating various bacterial infections, from respiratory tract infections to skin and soft tissue infections.

Patient-Centric Approach: The availability of CALTIS Dry Syrup in a dry syrup form caters to the needs of diverse patient populations, including children and those who have difficulty swallowing tablets.

Reduced Dosage Frequencies: The formulation of CALTIS Dry Syrup may allow for less frequent dosing, enhancing patient adherence to treatment regimens.

Potential Therapeutic Applications: CALTIS Dry Syrup’s antimicrobial activity makes it a valuable option for both community-acquired and hospital-acquired infections.

CALTIS Dry Syrup offers several key advantages in the realm of infectious disease treatment:

Broad-Spectrum Coverage: Calithromycin’s spectrum of activity makes CALTIS Dry Syrup a versatile option for treating various bacterial infections, from respiratory tract infections to skin and soft tissue infections.

Patient-Centric Approach: The availability of CALTIS Dry Syrup in a dry syrup form caters to the needs of diverse patient populations, including children and those who have difficulty swallowing tablets.

Reduced Dosage Frequencies: The formulation of CALTIS Dry Syrup may allow for less frequent dosing, enhancing patient adherence to treatment regimens.

Potential Therapeutic Applications: CALTIS Dry Syrup’s antimicrobial activity makes it a valuable option for both community-acquired and hospital-acquired infections.